Shaken baby syndrome and a triple-dose strategy for its prevention

Tanya Charyk Stewart1, Denise Polgar, Jason Gilliland

  • 1Trauma Program, London Health Sciences Centre and Children's Hospital, London, ON, Canada. tanya.charyk@lhsc.on.ca

The Journal of Trauma
|December 21, 2011
PubMed

Insights

Shaken Baby Syndrome (SBS) prevention education increased nurse knowledge and parent satisfaction. A triple-dose program targeting at-risk populations reduced infant injury mortality and morbidity.

Area of Science:

  • Pediatric Injury Prevention
  • Public Health Interventions
  • Epidemiology

Background:

  • Shaken Baby Syndrome (SBS) is a leading cause of infant mortality and morbidity due to inflicted traumatic brain injury.
  • A comprehensive, triple-dose prevention program was implemented to mitigate SBS incidence.

Purpose of the Study:

  • To describe the epidemiology of SBS.
  • To detail the triple-dose prevention program.
  • To evaluate the program's effectiveness in reducing SBS.

Main Methods:

  • Descriptive and spatial epidemiology of 54 SBS cases (1991-2010).
  • Dose 1: In-hospital nurse training and parent education (n>10,000).
  • Dose 2: Public health home visits.
  • Dose 3: Media campaign utilizing geographic information systems for targeted advertising.

Main Results:

  • 43% of severe infant injuries were intentional; 54 SBS cases identified with 19% mortality.
  • Nurse training increased knowledge by 47% (p < 0.001); 93% parent education compliance.
  • Parents rated the program highly useful, emphasizing coping strategies for infant crying.

Conclusions:

  • SBS is a severe, intentional injury with poor outcomes, necessitating effective prevention.
  • The triple-dose program enhanced knowledge and parent-reported usefulness, crucial for SBS prevention.
  • Targeted media campaigns and education on crying management can foster cultural change and reach high-need populations.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...